Form 4 for ALNY ALNYLAM PHARMACEUTICALS, INC.
Accepted 2025-03-05 00:00:00 ET · period of report 2025-03-03 · accession 0001735276-25-000032 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-03-05 | 2025-03-03+ | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | S - Sale | $242.92 | -2,557 | 26.4K | -9% | -$621.2K |
| D | 2025-03-05 | 2025-03-03 | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | A - Grant | $0.00 | +14.1K | 27.1K | +109% | $0 |
| D | 2025-03-05 | 2025-03-03 | ALNY | Garg Pushkal | CMO, EVP Dev, Med Affairs | A - Grant | $0.00 | +7,819 | 7,819 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-03 | S | D | 117 | $245.53 | 25,350 | D | — | — | (F13) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $245.07 to $245.74. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 2 | Common | Common Stock | 2025-03-03 | S | D | 1 | $248.36 | 26,323 | D | — | — | |
| 3 | Common | Common Stock | 2025-03-03 | S | D | 583 | $243.13 | 25,740 | D | — | — | (F11) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.62 to $243.58. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 4 | Common | Common Stock | 2025-03-04 | S | D | 147 | $239.25 | 25,203 | D | — | — | (F14) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $238.93 to $239.40. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 5 | Common | Common Stock | 2025-03-03 | S | D | 273 | $244.43 | 25,467 | D | — | — | (F12) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $244.04 to $244.80. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 6 | Common | Common Stock | 2025-03-03 | S | D | 5 | $247.35 | 26,324 | D | — | — | (F9) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $247.04 to $247.52. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 7 | Common | Common Stock | 2025-03-03 | S | D | 48 | $246.18 | 26,329 | D | — | — | (F8) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $246.00 to $246.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 8 | Common | Common Stock | 2025-03-04 | S | D | 343 | $240.92 | 24,860 | D | — | — | (F15) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $240.18 to $241.17. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 9 | Common | Common Stock | 2025-03-04 | S | D | 198 | $241.60 | 24,662 | D | — | — | (F16) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.21 to $242.02. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 10 | Common | Common Stock | 2025-03-04 | S | D | 120 | $242.70 | 24,542 | D | — | — | (F17) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.46 to $242.93. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 11 | Common | Common Stock | 2025-03-03 | A | A | 14,137 | $0.00 | 27,099 | D | — | — | (F1) These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. (F2) The Reporting Person has reported certain prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 14,137 newly awarded RSUs and 10,405 shares of common stock. The Reporting Person also holds 1,908 unvested RSUs that were previously reported in Table II. |
| 12 | Common | Common Stock | 2025-03-03 | S | D | 213 | $242.37 | 26,886 | D | — | — | (F4) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $241.87 to $242.86. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 13 | Common | Common Stock | 2025-03-03 | S | D | 235 | $243.36 | 26,651 | D | — | — | (F5) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $242.89 to $243.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 14 | Common | Common Stock | 2025-03-03 | S | D | 158 | $244.41 | 26,493 | D | — | — | (F6) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $243.90 to $244.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 15 | Common | Common Stock | 2025-03-03 | S | D | 116 | $245.26 | 26,377 | D | — | — | (F7) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $244.91 to $245.88. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 16 | Derivative | Stock Option (right to buy) | 2025-03-03 | A | A | 7,819 | $0.00 | 7,819 | D | $243.53 · — to 2035-03-03 | 7,819 Common Stock | (F20) The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vest in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. |